Figure 1

Sec62 is a prognostic marker for NSCLC patients. A, Patients with rSec62 < 2.1 exhibited significantly longer survival compared with those with rSec62 ≥ 2.1 (P < 0.001). B, The survival benefit of a low Sec62 protein level in the lung cancer tissue was significant in patients with SCC (P < 0.001). C, The survival benefit was not significant in patients with AC (P = 0.054).